Related Experiment Videos
Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol
Ling Zhang1, Hua-Ming Mai, Jing Zheng
1Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology Shanghai 200011, PR China.
Insights
Propranolol (PRN) treatment for infantile hemangiomas (IHs) shows plasma concentration varies with administration frequency. Once daily dosing causes early PRN elevation, while twice daily provides prolonged expression, aiding clinical decisions.
Area of Science:
- Pharmacology
- Pediatrics
- Dermatology
Background:
- Propranolol (PRN) is a first-line treatment for infantile hemangiomas (IHs).
- Pharmacokinetic data for PRN in infants with IH is lacking.
- Understanding PRN pharmacokinetics is crucial for optimizing IH treatment.
Purpose of the Study:
- To investigate the impact of PRN administration frequency on plasma concentrations in infants with IH.
- To provide essential pharmacokinetic parameters for clinical use.
Main Methods:
- Infants with IH received either once daily or twice daily PRN (1 mg/kg/d).
- Plasma PRN concentrations were measured over time.
- Pharmacokinetic parameters were analyzed based on dosing frequency.
Main Results:
- Single daily PRN administration led to an early peak in plasma PRN concentration.
- Twice daily PRN administration resulted in more prolonged plasma PRN expression.
- Dosing frequency significantly influences PRN pharmacokinetics in infants with IH.
Conclusions:
- PRN administration frequency affects plasma concentrations in infants with IH.
- Findings offer critical pharmacokinetic insights for tailoring PRN therapy in IH.
- This data supports evidence-based clinical practice for infantile hemangioma management.
Abstract:
Propranolol (PRN) has recently been recommended as the first-line medicine for complicated infantile hemangiomas (IHs), because of the significant effect. However, no pharmacokinetic parameters have ever been reported for infants who receive PRN treatment for IH. In this study, we show that plasma PRN concentration is affected by the frequency of administration of PRN. A single daily administration of PRN (1 mg/kg/d) resulted in an early elevation of plasma PRN compared to a twice a day administration of the same dose. In contrast, the twice a day application resulted in a more prolonged expression at a later time-point. Our findings provide pharmacokinetic parameters of PRN action in IH for clinic.
